

FORM PTO-1449  
(REV. 7-85)U.S. DEPT. OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC. NO.  
G-33302P1  
APPLICATION NO.  
10/031,874  
APPLICANT  
NANDI ET AL.  
FILING DATE  
JULY 31, 2003

Sheet 1 of 1

Group 1623

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,399,637	6/4/02	Filic et al.			
	AB	6,589,556	7/8/03	Cherukuri			
	AC	3,878,217	4/16/75	Carr et al.			
	AD	4,254,129	3/3/81	Carr et al.			
	AE	4,285,957	8/25/81	Carr et al.			
	AF	4,929,605	5/29/90	Domet et al.			
	AG	4,996,061	2/26/91	Webb et al.			
	AH	6,576,636	6/10/03	Webb et al.			
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

CASE G-33302P1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 457867826 US</u> Express Mail Label Number	<u>June 24, 2004</u> Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
NANDI ET AL.

EXAMINER: MICHAEL C. HENRY  
ART UNIT: 1623

APPLICATION NO: 10/631,874

FILED: JULY 31, 2003

FOR: FEXOFEDADINE COMPOSITION AND PROCESS FOR  
PREPARING

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080

Date: June 24, 2004

  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940  
(862) 778-7945